Inventprise

Executive Summary

Inventprise is a private biotechnology company headquartered in Redmond, Washington, focused on developing next-generation vaccines using its proprietary linker conjugation technology. Founded in 2014, the company is currently in Phase 1/2 clinical development for its lead candidate, IVT PCV-25, a 25-valent pneumococcal conjugate vaccine (PCV) designed for pediatric use. This vaccine aims to improve upon existing PCVs by providing broader serotype coverage and enhanced immune responses, potentially addressing unmet needs in preventing pneumococcal disease. Inventprise's platform enables precise antigen presentation, which may lead to higher efficacy and reduced manufacturing costs. The company operates in the competitive vaccines market but differentiates itself through its innovative conjugation chemistry. As a private entity with limited public financial disclosures, the company's risk profile is elevated due to early-stage development and reliance on successful clinical outcomes. However, the global PCV market, valued at over $7 billion annually, presents significant commercial opportunity if IVT PCV-25 demonstrates favorable safety and immunogenicity data in ongoing trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim immunogenicity data for IVT PCV-2560% success
• Q2 2027Regulatory meeting (e.g., FDA Type B) to discuss Phase 3 design70% success